Journal of Brain and Neurology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Commentary - Journal of Brain and Neurology (2023) Volume 6, Issue 3

Expanding spectrum of antibody-associated cerebellar ataxia

Nico Gebhardt*

Department of Neurosciences

*Corresponding Author:
Nico Gebhardt
Department of Neurosciences
Nagoya University
Japan
E-mail:nico.gebhardt@nagoya-u.ac.jp

Received:17-Apr-2023, Manuscript No. AAJBN-23-97948; Editor assigned:20-Apr-2023, PreQC No. AAJBN-23-97948(PQ); Reviewed:04-May-2023, QC No. AAJBN-23-97948; Revised:08-May-2023, Manuscript No. AAJBN-23-97948(R); Published:15-May-2023, DOI:10.35841/ aajbn-6.2.144

Citation: Gebhardt N. Expanding spectrum of antibody-associated cerebellar ataxia. 2023;6(2):144

Visit for more related articles at Journal of Brain and Neurology

Introduction

Antibody-associated cerebellar ataxia is a rare neurological disorder that affects the cerebellum, a region of the brain responsible for motor coordination and balance. It is caused by antibodies that target proteins in the cerebellum, leading to inflammation and damage to the cerebellar tissue. In recent years, the spectrum of antibody-associated cerebellar ataxia has expanded, with new antibody targets and clinical features being identified. One of the earliest antibodies associated with cerebellar ataxia is anti-Yo antibody, which targets a protein called CDR2 found in Purkinje cells, the main type of neuron in the cerebellum. Anti-Yo antibody is most commonly found in women with gynecological or breast cancer, and the onset of cerebellar ataxia is typically gradual and progressive. Other antibodies targeting Purkinje cells have since been identified, including anti-Tr antibody, which targets a protein called Tr, and anti-Zic4 antibody, which targets a transcription factor involved in cerebellar development. These antibodies are also associated with gynecological or breast cancer, and the clinical features of cerebellar ataxia vary depending on the antibody type [1].

In addition to antibodies targeting Purkinje cells, antibodies targeting other types of cerebellar neurons have been identified. Anti-Ma2 antibody targets a protein called Ma2 found in neurons in the limbic system and brainstem, and is associated with testicular or lung cancer. Anti-Ri antibody targets a protein called Ri found in neurons in the brainstem and spinal cord, and is associated with breast or small-cell lung cancer. The clinical features of cerebellar ataxia associated with these antibodies may include additional neurological symptoms, such as memory loss or autonomic dysfunction. More recently, antibodies targeting the voltage-gated potassium channel complex (VGKC) have been identified in some cases of cerebellar ataxia. These antibodies target proteins involved in the regulation of neuronal excitability, and are associated with a range of neurological and psychiatric symptoms, including seizures, cognitive impairment, and psychosis. In some cases, cerebellar ataxia may be the predominant clinical feature [2].

The identification of new antibody targets in cerebellar ataxia has important implications for diagnosis and treatment. Patients with antibody-associated cerebellar ataxia may benefit from immunotherapy, such as intravenous immunoglobulin (IVIg) or plasmapheresis, which aim to remove or reduce the level of antibodies in the blood. Early detection of the underlying cancer is also important, as treatment of the cancer may lead to improvement in the neurological symptoms. The expanding spectrum of antibody-associated cerebellar ataxia highlights the importance of recognizing the different clinical and immunological features associated with different antibody types. Accurate diagnosis and appropriate treatment may lead to improved outcomes for patients with this rare but debilitating condition.Antibody-associated cerebellar ataxia is a heterogeneous disorder, with a variety of clinical presentations and associated antibodies. In addition to the antibodies mentioned earlier, other antibodies have been identified in cerebellar ataxia, including anti-GAD65 antibody, which targets a protein involved in the synthesis of gamma-aminobutyric acid (GABA), an important neurotransmitter in the cerebellum. Anti-GAD65 antibody is associated with type 1 diabetes mellitus and other autoimmune disorders, and may also cause other neurological symptoms such as stiff-person syndrome [3].

Another important group of antibodies in cerebellar ataxia is the anti-glutamate receptor (GluR) antibodies, which target proteins involved in the regulation of synaptic transmission. Anti-GluR antibodies are associated with a range of neurological disorders, including cerebellar ataxia, epilepsy, and psychiatric disorders. The most common anti-GluR antibodies associated with cerebellar ataxia are anti-mGluR1 and anti-GluRδ2 antibodies. Anti-mGluR1 antibody is associated with Hodgkin lymphoma and may also cause other neurological symptoms such as encephalitis, whereas anti-GluRδ2 antibody is associated with gluten ataxia and may also cause neuropathy [4].

The expanding spectrum of antibody-associated cerebellar ataxia has also led to the identification of new clinical syndromes. For example, anti-Ca antibody, which targets a calcium-binding protein called alpha-1A subunit of P/Q-type voltage-gated calcium channels, is associated with a rare disorder called paraneoplastic cerebellar degeneration with anti-Ca antibodies. This syndrome is characterized by rapidly progressive cerebellar ataxia, dysarthria, and other neurological symptoms, and is often associated with small-cell lung cancer. The identification of new antibody targets in cerebellar ataxia has also improved our understanding of the pathophysiology of the disorder. For example, the identification of anti-VGKC antibodies has led to the recognition of a new subtype of autoimmune encephalitis called limbic encephalitis with VGKC-complex antibodies. This syndrome is characterized by seizures, memory loss, and other neurological and psychiatric symptoms, and may also cause cerebellar ataxia. The expanding spectrum of antibody-associated cerebellar ataxia highlights the complexity of this disorder and the importance of a comprehensive diagnostic evaluation. A high index of suspicion for autoimmune etiologies is warranted, as early recognition and treatment may improve outcomes. Future research may also lead to the identification of new antibody targets and novel therapies for this rare but devastating disorder [5].

Conclusion

The expanding spectrum of antibody-associated cerebellar ataxia highlights the complexity of this disorder and the importance of recognizing the different clinical and immunological features associated with different antibody types. Accurate diagnosis and appropriate treatment may lead to improved outcomes for patients with this rare but debilitating condition. The identification of new antibody targets in cerebellar ataxia has also improved our understanding of the pathophysiology of the disorder, and may lead to the development of new therapies in the future. Further research is needed to better understand the underlying mechanisms of antibody-associated cerebellar ataxia and to improve the diagnosis and treatment of this challenging condition.

References

  1. Anderson NE, Budde-Steffen C, Wiley RG, et al. A variant of the anti-Purkinje cell antibody in a patient with paraneoplastic cerebellar degeneration.. Neurology. 1988;38(7):1018-26.

    2. Indexed at, Google Scholar, Cross Ref

  2. Geis C, Weishaupt A, Grunewald B, et al. Human stiff-person syndrome IgG induces anxious behavior in rats. PLoS One. 2011;6(2):e16775.

    3. Indexed at, Google Scholar,Cross Ref

  3. Shiraga S, Adamus G. Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway. J Neuroimmunol. 2002;132(2):72-82.

    4. Indexed at, Google Scholar, Cross Ref

  4. Lundmark R, Doherty GJ, Howes MT, et al. The GTPase-activating protein GRAF1 regulates the CLIC/GEEC endocytic pathway. Curr Biol. 2008;18(22):1802-08.

    5. Indexed at, Google Scholar, Cross Ref

  5. Sommer C, Weishaupt A, Brinkhoff J, et al. . Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet. 2005;365(9468):1406-11.

    6. Indexed at, Google Scholar, Cross Ref

Get the App